Evotec SE EVT

Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the Cancer Science Institute of Singapore London, United Kingdom, 29 September 2026 – 4BIO Capital,

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that Chief Scientific Officer (CSO) Dr. Cord Dohrmann will step down effective September 30, 2026. The decision for Dr. Dohrmann to step down from his position was made by mutual consent between Dr. Dohrmann and the Company.

Giovanni Amabile, Founder and CEO Giovanni Amabile, Founder and CEO of Aptadir Therapeutics Funds will advance novel class of RNA inhibitors to reverse intractable genetic conditions Seed is led by 4BIO Capital with follow-on participation from the company's original pre-seed investor EXTEND (CDP Venture Capital SGR, Angelini Ventures and Evotec SE) Science originates from three leading institutions – the Beth Israel Deaconess Medical Center, the Italian Research National Council (CNR) and the C

Pharma R&D outsourcing is rising as CROs use AI, genomics and advanced screening to cut costs, accelerate discovery, improve compliance and support targeted therapies.Dublin, Sept. 24, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Services - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Services was estimated at US$10.8 Billion in 2025 and is projected to reach US$26.3 Billion by 2032, growing at a CAGR of 13.6% from 2025 to

Stricter safety rules, drug innovation and CRO outsourcing drive demand, while imaging, CRISPR and data analytics improve testing and reduce animal use.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "In Vivo Toxicology - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for In Vivo Toxicology was estimated at US$4.5 Billion in 2025 and is projected to reach US$6.0 Billion by 2032, growing at a CAGR of 4.3% from 2025 to 2032. This comprehensive re

Pharma companies are expanding drug discovery outsourcing to cut costs, access CRO expertise and AI tools, speed pipelines, manage regulatory complexity, and advance targeted therapies.Dublin, Sept. 23, 2026 (GLOBE NEWSWIRE) -- "Drug Discovery Outsourcing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Drug Discovery Outsourcing was estimated at US$2.8 Billion in 2025 and is projected to reach US$4.5 Billion by 2032, growing at a CAGR

AI-driven screening, advanced imaging and demand for targeted therapies are accelerating FBDD, creating opportunities in oncology, neurology and traditionally undruggable targets.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Fragment-based Drug Discovery - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Fragment-based Drug Discovery was valued at US$977 Million in 2024 and is projected to reach US$1.6 Billion by 2030, growing at a CAGR of

Automation, robotics, AI, cloud platforms and RFID are transforming compound management, creating opportunities in drug discovery, biotech, materials science and distributed research.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "Compound Management - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for Compound Management was estimated at US$396.8 Million in 2025 and is projected to reach US$1.0 Billion by 2032, growing at a CAGR of 14.7% from

Demand is rising for faster, accurate ADME-Tox testing, driven by complex biologics, tighter regulation, personalized medicine, and adoption of high-throughput, in vitro and in silico methods.Dublin, Sept. 22, 2026 (GLOBE NEWSWIRE) -- "ADME-Toxicology Testing - Global Strategic Business Report" has been added to ResearchAndMarkets.com's offering.The global market for ADME-Toxicology Testing was valued at US$10 Billion in 2024 and is projected to reach US$18.8 Billion by 2030, growing at a CAGR o

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the initiation of a Phase 1 clinical trial evaluating JST-018, a cocktail of investigational monoclonal antibodies targeting orthopoxviruses, developed by its biologics CDMO subsidiary Just – Evotec Biologics under the U.S. Department of War's Accelerated Antibodies Program.

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) and Plectonic Biotech today announced a research collaboration to explore a novel immunotherapy approach for solid tumors. The collaboration addresses key challenges that have so far limited the successful application of traditional T cell engager therapies in solid tumors by combining Plectonic's programmable LOGIBODY® technology with Evotec's proprietary BiTco platform.

Why Odyssey Therapeutics Stock Is Back In Focus Odyssey Therapeutics (ODTX) is drawing attention after reporting second quarter 2026 results that showed a larger net loss alongside a sharp change in reported loss per share from continuing operations. For the quarter ended June 30, 2026, Odyssey Therapeutics reported a net loss of US$52.79 million compared with US$41.24 million a year earlier. Basic and diluted loss per share from continuing operations was US$1.74, while the prior year figure...

The partnership intends to leverage complementary scientific strengths to boost early-stage research and produce new medicines.

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced that it has entered a strategic R&D collaboration with Odyssey Therapeutics, Inc. (NASDAQ: ODTX) to discover potential new treatments in autoimmune and inflammatory diseases.

Evotec SE (NASDAQ: EVO) (Frankfurt Prime Standard: EVT) today announced the expansion of its Just – Evotec Biologics services with J.TRAIN, a new offering that enables biopharmaceutical companies to deploy Evotec's proprietary continuous manufacturing technology directly within their own facilities on a turnkey basis. J.TRAIN brings together prefabricated modular cleanrooms and industry-standard manufacturing equipment with Just – Evotec Biologics' cGMP-compliant process automation, designed to

Evotec SE (NASDAQ: EVO; Frankfurt Prime Standard: EVT) today announced the results of its Annual General Meeting.

Recent share performance and business snapshot Evotec (XTRA:EVT) drew investor attention after a mixed share performance, with the stock roughly flat in the past day, down over the past month, yet up over the past 3 months, against a backdrop of ongoing losses and modest revenue growth. See our latest analysis for Evotec. At around €4.93 per share, Evotec’s recent 7 day and year to date share price declines, alongside a 1 year total shareholder return fall of 31.1%, suggest sentiment has...

HAMBURG, DE / ACCESS Newswire / June 2, 2026 / Evotec SE (NASDAQ:EVO)(Frankfurt Prime Standard:EVT) today announced the appointment of Rui Wang as Executive Vice President, Head of Global In Silico and AI. Mr. Wang brings to Evotec more than 20 years ...

U.S. stock futures were mixed this morning, with the Dow futures falling around 100 points on Wednesday. Shares of QuickLogic Corp (NASDAQ:QUIK) fell in pre-market trading after the company reported worse-than-expected first-quarter financial results. QuickLogic reported quarterly losses of 8 cents per share which missed the analyst consensus estimate of losses of 5 cents per share. The company reported quarterly sales of $5.051 million which missed the analyst consensus estimate of $5.508 milli

Evotec SE (NASDAQ:EVO) is one of the 10 Best Penny Stocks to Buy Before They Explode. On May 4, 2026, Evotec SE (NASDAQ:EVO) announced the nomination of a small molecule preclinical development candidate from its multi-target drug discovery alliance with Almirall focused on medical dermatology. The program is aimed at developing new therapies for immune-mediated […]